© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review current treatment strategies and challenges for the management of myelofibrosis and the evolving treatment landscape of the disease.
August 30th 2021
Srdan Verstovsek, MD, PhD, describes the classic signs and symptoms of primary myelofibrosis (PMF), along with goals of therapy.
Aaron Gerds, MD, MS, provides insight on determining low- vs high-risk primary myelofibrosis, the role of molecular status on treatment, and his approach toward symptom burden assessment.
September 7th 2021
Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review key updates to NCCN guidelines for primary myelofibrosis and discuss treatment options for the disease.
Experts in hematology/oncology comment on challenges in treating patients with myelofibrosis.
September 13th 2021
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the importance of allele burden in myelofibrosis (MF) and how cytopenias can limit treatment options for patients with myelofibrosis.
Hematology/oncology experts review their approach to monitoring treatment response in myelofibrosis (MF) and when they would consider switching therapies.
September 20th 2021
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the impact of pathways, including JAK-STAT, on myelofibrosis disease progression and discuss considerations for the use of JAK inhibitors.
Expert hematologist/oncologists review the use of pacritinib for the treatment of myelofibrosis, as seen in the PERSIST-1 and PERSIST-2 trials.